AIMS: The aim was to assess potential interaction between methotrexate (MTX) and proton pump inhibitors (PPIs) in patients receiving high-dose MTX. METHODS: Records of 56 adults receiving 201 cycles of MTX were reviewed to determine effects of PPI administration on MTX elimination. Repeated-measures logistic regressions and Cox regressions were performed to evaluate the possible drug interaction. RESULTS: Despite a significant difference between those receiving a PPI and not receiving a PPI in median MTX levels at 24 (8.0 vs. 3.9 μmol l(-1) , respectively, P = 0.013) and 72 h after MTX administration (0.08 vs. 0.05 μmol l(-1) , respectively, P = 0.037), there was no difference between those receiving a PPI and not receiving a PPI in the proportion of patients experiencing delayed elimination at 24 (19.2% vs. 20.2%, respectively, P = 1.000) and 72 h (36.2% vs. 33.7%, respectively, P = 0.765). When data were analysed using Cox regression, controlling for multiple cycles of MTX per patient, PPI use was not a significant predictor of time to MTX < 0.1 μmol l(-1) . When the clustering effect of multiple cycles of MTX per patient was controlled for, co-administration of PPIs was not a significant predictor of MTX level (P = 0.969). A comparison of patients with delayed elimination at any time point and those without delayed elimination indicated that PPI use was not a significant predictor of delayed elimination (P = 0.607). CONCLUSIONS: This study does not support previous findings of a significant interaction between PPIs and MTX. Based on these results, the clinical significance of any potential interaction is likely to be small.
AIMS: The aim was to assess potential interaction between methotrexate (MTX) and proton pump inhibitors (PPIs) in patients receiving high-dose MTX. METHODS: Records of 56 adults receiving 201 cycles of MTX were reviewed to determine effects of PPI administration on MTX elimination. Repeated-measures logistic regressions and Cox regressions were performed to evaluate the possible drug interaction. RESULTS: Despite a significant difference between those receiving a PPI and not receiving a PPI in median MTX levels at 24 (8.0 vs. 3.9 μmol l(-1) , respectively, P = 0.013) and 72 h after MTX administration (0.08 vs. 0.05 μmol l(-1) , respectively, P = 0.037), there was no difference between those receiving a PPI and not receiving a PPI in the proportion of patients experiencing delayed elimination at 24 (19.2% vs. 20.2%, respectively, P = 1.000) and 72 h (36.2% vs. 33.7%, respectively, P = 0.765). When data were analysed using Cox regression, controlling for multiple cycles of MTX per patient, PPI use was not a significant predictor of time to MTX < 0.1 μmol l(-1) . When the clustering effect of multiple cycles of MTX per patient was controlled for, co-administration of PPIs was not a significant predictor of MTX level (P = 0.969). A comparison of patients with delayed elimination at any time point and those without delayed elimination indicated that PPI use was not a significant predictor of delayed elimination (P = 0.607). CONCLUSIONS: This study does not support previous findings of a significant interaction between PPIs and MTX. Based on these results, the clinical significance of any potential interaction is likely to be small.
Authors: M Joerger; A D R Huitema; H J G D van den Bongard; P Baas; J H Schornagel; J H M Schellens; J H Beijnen Journal: Br J Clin Pharmacol Date: 2006-07 Impact factor: 4.335
Authors: Ryan J Beechinor; Patrick A Thompson; Michael F Hwang; Ryan C Vargo; Lisa R Bomgaars; Jacqueline G Gerhart; ZoAnn E Dreyer; Daniel Gonzalez Journal: Clin Pharmacokinet Date: 2019-07 Impact factor: 6.447
Authors: David A Johnson; Philip O Katz; David Armstrong; Henry Cohen; Brendan C Delaney; Colin W Howden; Peter Katelaris; Radu I Tutuian; Donald O Castell Journal: Drugs Date: 2017-04 Impact factor: 9.546